« Previous
Next »
Titles
- S1B(R1) addendum to S1B testing for carcinogenicity of pharmaceuticals: guidance for industry1
- Safety considerations for container labels and carton labeling design to minimize medication errors1
- Scientific integrity: HHS agencies need to develop procedures and train staff on reporting and addressing political interference : report to congressional addressees1
- Scientific integrity: HHS agencies need to develop procedures and train staff on reporting and addressing political interference : testimony before the Select Subcommittee on the Coronavirus Crisis, Committee on Oversight and Reform, House of Representatives1
- Size, shape, and other physical attributes of generic tablets and capsules: guidance for industry1
- Some Medicare Advantage Organization denials of prior authorization requests raise concerns about beneficiary access to medically necessary care1
- State responses to FASD: effective strategies and ongoing challenges1
- State use of value-based payment in nursing facilities1
- Strengthening the child nutrition programs1
- Studying multiple versions of a cellular or gene therapy product in an early-phase clinical trial: guidance for industry1
- Submitting documents using real-world data and real-world evidence to FDA for drug and biological products1
- Suicide prevention: DOD should enhance oversight, staffing, guidance, and training affecting certain remote installations : report to congressional committees1
- Supplements for approved Premarket Approval (PMA) or Humanitarian Device Exemption (HDE) submissions during the Coronavirus Disease 2019 (COVID-19) public health emergency (revised): guidance for Industry and Food and Drug Administration staff1
- Surgical sutures: performance criteria for safety and performance based pathway : guidance for industry and Food and Drug Administration staff1